يعرض 1 - 20 نتائج من 39 نتيجة بحث عن '"slowed down"', وقت الاستعلام: 0.46s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
    Academic Journal

    المساهمون: Maffulli, Nicola, Gougoulias, Nikolao, Maffulli, Gayle D, Oliva, Francesco, Migliorini, Filippo

    Relation: info:eu-repo/semantics/altIdentifier/pmid/34581220; info:eu-repo/semantics/altIdentifier/wos/WOS:000703239900001; volume:43; firstpage:244; lastpage:252; numberofpages:9; journal:FOOT & ANKLE INTERNATIONAL; https://hdl.handle.net/11573/1694862; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85116040252

  3. 3
    Academic Journal
  4. 4
    Academic Journal
  5. 5
  6. 6
  7. 7
    Periodical

    المؤلفون: Spadaro, Katherine

    المصدر: Quadrant Magazine. Jul/Aug2021, Vol. 65 Issue 7, p53-53. 1p.

    Reviews & Products: AS My Dog Slowed Down (Poem)

  8. 8
  9. 9
  10. 10
    Conference

    المؤلفون: Flavia Marinelli

    المساهمون: V. Spiwok, O. Mat’átková, M. Rollová, A. Miškovská, M. Kulišová, L. Paulová, J. Káš, Marinelli, Flavia

    مصطلحات موضوعية: Discovery of novel antibiotics has dramatically slowed down. After the ‘golden era’ peaked around 1950s, the number of antibiotics marketed each decade has declined. Conversely, the rapid spread of antibiotic resistance among pathogenic bacteria makes the development of novel drugs compulsory. Notably, ESKAPE pathogens (six multidrug-resistant, nosocomial pathogens: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.), were recently included by the World Health Organization in the list of the life-threatening disease agents which need to be tackle using new drugs. Many are the factors, which exert a negative impact on the antibiotic discovery rate: from the unease to identify new essential susceptible targets and to discover novel active chemical entities, to the regulatory challenges and the limited economic returns that often discourage pharmaceutical companies from investing into the field. In this post-antibiotic era, the best hope for developing a new generation of antibiotics is to discover novel microbial natural products by combining the classical successful biological activity-guided screening (so called Waksman platform) with the perspectives opened by the new genomic tools for genome mining and for the rational engineering of homologous and heterologous hosts. In this presentation, we focus on the exploitation of these tools for discovering and developing novel and old glycopeptide antibiotics (GPAs) facing the spread of multi-drug resistant gram positives. Genome sequencing has in fact recently revealed the organization of GPA biosynthetic gene clusters in pharmaceutically valuable actinobacteria, including long known GPA-producers, as well as in novel producing strains and metagenomic DNA. In addition, although the global regulation of GPA biosynthesis is still largely unexplored, the pathway specific regulation controlling the expression of BGCs is being elucidated in model systems, paving the way to better understand how to effectively produce GPAs for clinical practice.

    Relation: info:eu-repo/semantics/altIdentifier/isbn/978-80-7592-092-8; ispartofbook:Book of abstract of BioTech 2020 & 8th Czech-Swiss Symposium with Exhibition; BioTech 2020 & 8th Czech-Swiss Symposium with Exhibition; firstpage:28; lastpage:28; numberofpages:1; http://hdl.handle.net/11383/2113290

  11. 11

    المؤلفون: Marinelli, Flavia

    مصطلحات موضوعية: Acinetobacter baumannii, Staphylococcus aureus, paving the way to better understand how to effectively produce GPAs for clinical practice, the pathway specific regulation controlling the expression of BGCs is being elucidated in model systems, to the regulatory challenges and the limited economic returns that often discourage pharmaceutical companies from investing into the field. In this post-antibiotic era, Discovery of novel antibiotics has dramatically slowed down. After the ‘golden era’ peaked around 1950s, and Enterobacter spp.), nosocomial pathogens: Enterococcus faecium, ESKAPE pathogens (six multidrug-resistant, the best hope for developing a new generation of antibiotics is to discover novel microbial natural products by combining the classical successful biological activity-guided screening (so called Waksman platform) with the perspectives opened by the new genomic tools for genome mining and for the rational engineering of homologous and heterologous hosts. In this presentation, Klebsiella pneumoniae, were recently included by the World Health Organization in the list of the life-threatening disease agents which need to be tackle using new drugs. Many are the factors, as well as in novel producing strains and metagenomic DNA. In addition, which exert a negative impact on the antibiotic discovery rate: from the unease to identify new essential susceptible targets and to discover novel active chemical entities, including long known GPA-producers, Discovery of novel antibiotics has dramatically slowed down. After the ‘golden era’ peaked around 1950s, the number of antibiotics marketed each decade has declined. Conversely, the rapid spread of antibiotic resistance among pathogenic bacteria makes the development of novel drugs compulsory. Notably, ESKAPE pathogens (six multidrug-resistant, nosocomial pathogens: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.), were recently included by the World Health Organization in the list of the life-threatening disease agents which need to be tackle using new drugs. Many are the factors, which exert a negative impact on the antibiotic discovery rate: from the unease to identify new essential susceptible targets and to discover novel active chemical entities, to the regulatory challenges and the limited economic returns that often discourage pharmaceutical companies from investing into the field. In this post-antibiotic era, the best hope for developing a new generation of antibiotics is to discover novel microbial natural products by combining the classical successful biological activity-guided screening (so called Waksman platform) with the perspectives opened by the new genomic tools for genome mining and for the rational engineering of homologous and heterologous hosts. In this presentation, we focus on the exploitation of these tools for discovering and developing novel and old glycopeptide antibiotics (GPAs) facing the spread of multi-drug resistant gram positives. Genome sequencing has in fact recently revealed the organization of GPA biosynthetic gene clusters in pharmaceutically valuable actinobacteria, including long known GPA-producers, as well as in novel producing strains and metagenomic DNA. In addition, although the global regulation of GPA biosynthesis is still largely unexplored, the pathway specific regulation controlling the expression of BGCs is being elucidated in model systems, paving the way to better understand how to effectively produce GPAs for clinical practice, Pseudomonas aeruginosa, we focus on the exploitation of these tools for discovering and developing novel and old glycopeptide antibiotics (GPAs) facing the spread of multi-drug resistant gram positives. Genome sequencing has in fact recently revealed the organization of GPA biosynthetic gene clusters in pharmaceutically valuable actinobacteria, the number of antibiotics marketed each decade has declined. Conversely, although the global regulation of GPA biosynthesis is still largely unexplored, the rapid spread of antibiotic resistance among pathogenic bacteria makes the development of novel drugs compulsory. Notably

  12. 12
  13. 13
  14. 14
  15. 15
    Academic Journal

    المصدر: Vestnik dermatologii i venerologii; Vol 90, No 1 (2014); 37-44 ; Вестник дерматологии и венерологии; Vol 90, No 1 (2014); 37-44 ; 2313-6294 ; 0042-4609

    وصف الملف: application/pdf

  16. 16
    Periodical

    المؤلفون: OSWALD, ALICE

    المصدر: Poetry. Jun2016, Vol. 208 Issue 3, p290-290. 1p.

    مصطلحات موضوعية: BLACKBIRDS

    Reviews & Products: SLOWED-Down Blackbird (Poem)

  17. 17
    Academic Journal
  18. 18
    Academic Journal
  19. 19
  20. 20